In this special episode of Healthcare Unfiltered, Dr. Tanios Bekaii-Saab, of the Mayo Clinic, joins Dr. Chadi Nabhan to discuss the most groundbreaking studies unveiled at the 2024 ASCO GI Symposium, including an examination of the crucial, previously reported data from IMbrave050 and EMERALD-1.
Liver Cancer
Lenvatinib is a common treatment for patients with uHCC, and has been used with pembrolizumab for other diseases.
The TransMet trial was developed to determine the efficacy of chemotherapy with LT compared with chemotherapy alone.
ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
A personalized therapeutic cancer vaccine may increase patient response to PD-1 inhibitors.
The study’s primary end points were objective response rate, overall survival, and safety.
The latest guideline update includes recommendations for first-, second-, and third-line therapy options.
Researchers investigated the potential of the phosphatidylserine-targeting antibody bavituximab plus pembrolizumab.
The CheckMate 040 trial reported that nivolumab monotherapy benefits patients who have an acceptable safety profile.
Advertisement
Featured Podcast
Advertisement
